|
|

Title: Stabilizers for lyophilized mumps vaccines
United States Patent: 6,051,238
Inventors: Volkin; David B. (Doylestown, PA); Burke; Carl J.
(Pennsburg, PA); Sheu; Su-Pi (Maple Glenn, PA)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Appl. No.: 993493
Filed: December 18, 1997
Abstract
Vaccine stabilizers, vaccine formulations and lyophilized vaccines with
enhanced thermostability are disclosed. The vaccine formulations comprise
an increased amount of a 6-carbon polyhydric alcohol (such as sorbitol),
an increase amount of a disaccharide (such as sucrose) and an amount of a
physiologically active buffer to adjust the pH from about 6.0 to about
7.0.
SUMMARY OF THE INVENTION
The present invention relates to vaccine stabilizers,
vaccine formulations, and live attenuated lyophilized vaccines which
impart increased thermostability.
The vaccine formulation of the present invention comprises viral and
stabilizer components which result on a gram per liter basis from about 15
to about 90 grams per liter of a 6-carbon polyhydric alcohol, including
but not limited to sorbitol, mannitol and dulcitol; from about 10 to about
70 grams per liter of a disaccharide, including but not limited to
sucrose, lactose, maltose or trehalose and an amount of a physiologically
active buffer to adjust the pH from about 6.0 to about 7.0. It is
preferred in the present invention that the 6-carbon polyhydcic alcohol be
sorbitol and the disaccharide be sucrose.
In another embodiment of the present invention, the vaccine formulation
contains sorbitol as the 6-carbon polyhydric alcohol, from about 15 to
about 90 grams per liter; the disaccharide sucrose, from about 10 to about
70 grams per liter; and, the pH of the vaccine formulation is controlled
through citrate-phosphate combinations to ensure buffering across a pH
range of about 6.0 to about 7.0 by one of two approaches: addition of
phosphate at a concentration from about 7.5 mM to about 75 mM or addition
of a phosphate:citrate combination with a phosphate concentration from
about 7.5 mM to about 75 mM and a citrate concentration from about 30 mM
to about 0.4M.
In an additional embodiment of the present invention, the vaccine
formulation contains sorbitol as the 6-carbon polyhydric alcohol, from
about 15 to about 90 grams per liter; the disaccharide sucrose, from about
10 to about 70 grams per liter; and, the pH of the vaccine formulation is
controlled through addition of a phosphate buffer to ensure buffering
across the preferred pH range of about 6.0 to about 7.0
The vaccine formulations of the present invention preferably include one
or more additional components, alone or in a biologically effective
combination, which provides a vaccine with enhanced thermostability
characteristics; including but not limited to hydrolyzed gelatin from
about 10 to 50 grams per liter, sodium chloride from about 1 to about 6
grams per liter; sodium bicarbonate in amounts to about 1.5 g/l,
preferable from about 0.2 g/l to about 1.2 g/l; human serum albumin at
about 0.5 to 1.0 gram per liter, or approximately 0.3 to about 1.0% by dry
weight of the lyophilized form of the vaccine; and cell culture medium
which is a nutrient medium which promotes cell growth in vitro, including
but not limited to known cell culture media such as Solution 199, Medium
T, Medium O, Dubecco's Modified Eagles Medium, Mjninl Essential Medium,
and Basal Medium Eagle. Preferred media components include biologically
effective amounts of Medium O, Medium T and Solution 199. Other components
of the vaccine formulation of the present invention may include, but are
not limited to, biologically active amounts of an antibiotic (e.g.,
neomycin) and a pH indicator (e.g., phenol red).
Therefore, vaccine formulations of the present invention may comprise
sorbitol as the 6-carbon polyhydric alcohol, from about 15 to about 90
grams per liter; the disaccharide sucrose, from about 10 to about 70 grams
per liter; a biologically effective concentration of a cell culture medium
(preferably Medium O), a biologically effective concentration of a salt
(preferably NaCl), a biologically effective concentration of a bicarbonate
(preferably NaHCO3), a citrate-phosphate combination to ensure
buffering across the preferred pH range as well as several additional
components, including but not limited to neomycin and phenol red. The
addition of bicarbonate in varying amounts may alter the formulation pH
within a biologically acceptable range.
The vaccine formulations of the present invention may also comprise
sorbitol as the 6-carbon polyhydric alcohol, from about 15 to about 90
grams per liter; the disaccharide sucrose, from about 10 to about 70 grams
per liter; a biologically effective concentration of a cell culture medium
(preferably Medium O), a biologically effective concentration of a salt
(preferably NaCl), a biologically effective concentration of a bicarbonate
(preferably NaHCO3), a phosphate buffer to ensure the preferred
pH range as well as several additional components, including but not
limited to neomycin and phenol red. Again, the addition of bicarbonate in
varying amounts may alter the formulation pH within a biologically
acceptable range.
An integral aspect of a preferred portion of the vaccine formulations of
the present invention is the dual presence of sucrose and sorbitol. The
range of sorbitol is from about 15 to about 90 grams per liter while
sucrose is present in the range from about 10 to about 70 grams per liter.
A preferred range of sorbitol in the vaccine formulations of the present
invention is from about 35 to about 75 grams per liter. An especially
preferred range of sorbitol in the vaccine formulation of the present
invention is from about 45 grams per liter to about 60 grams per liter. A
preferred range of sucrose in the vaccine formulations of the present
invention is from about 15 to about 55 grams per liter. An especially
preferred range of sucrose in the vaccine formulation of the present
invention is from about 20 grams per liter to about 45 grams per liter.
Claim 1 of 18 Claims
1. A vaccine comprising an attenuated virus and
stabilizer, wherein said vaccine comprises
28.94 grams per liter of hydrolyzed gelatin, 48.94 grams per liter of
sorbitol, 10.59 grams per liter of phosphate, 4.92 grams per liter NaCl,
43.74 grams per liter of sucrose, 0.34 grams per liter bicarbonate, 0.66
grams per liter glucose, 0.62 grams per liter HSA, and 2.53 grams per
liter of citrate;
wherein the virus includes at least an attenuated mumps virus.
____________________________________________
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full
patent.
|